Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mobile clinic brings one-stop HIV and addiction care to those who inject drugs

NCT ID NCT04804072

Disease control Sponsor: HIV Prevention Trials Network Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a mobile health unit that offers HIV prevention, treatment, and medication for opioid use disorder all in one place helps people who inject drugs stay on treatment. About 447 adults with opioid use disorder took part. The goal was to see if this approach increases use of HIV medicines and addiction treatment at 26 and 52 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

447 people

The number who actually took part.

Started

Jun 2021

Finished

Dec 2024

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 years of age * Urine test positive for recent opioid use and with evidence of recent injection drug use ("track marks") * Diagnosed with OUD per Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 * Able and willing to give informed consent * Willing to start MOUD treatment * Able to successfully complete an Assessment of Understanding * Self-reported sharing injection equipment and/or condomless sex in the last three months with partners of HIV-positive or unknown status * Able to provide adequate locator information * Confirmed HIV status, as defined in the HPTN 094 Study Specific Procedures Manual Exclusion Criteria: * Urine testing that is not negative for methadone within 30 days prior to Enrollment is exclusionary, unless verified hospital records show methadone received as a medication for hospitalization only during the screening period. A volunteer may provide a sample for urine testing more than once during the screening period in order to achieve a negative result. If this criterion cannot be met within 30 days from the start of screening, the individual will be considered a screen failure and the volunteer has up to two more screening chances to successfully complete the screening process again. * Received MOUD in the 30 days prior to enrollment by self-report * Co-enrollment in any other interventional study unless approved by the Clinical Management Committee (CMC)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug use are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease opiate dependence opioid abuse substance abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug use HIV infections Opioid use Opioid-use disorder

Contacts and locations

Locations

  • Bronx Prevention Center CRS

    The Bronx, New York, 10451, United States

  • George Washington University CRS

    Washington D.C., District of Columbia, 20007, United States

  • Houston AIDS Research Team CRS

    Houston, Texas, 77030, United States

  • Penn Prevention CRS

    Philadelphia, Pennsylvania, 19104, United States

  • UCLA Vine Street Clinic

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.